VARIBAR PUDDING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VARIBAR PUDDING (VARIBAR PUDDING).
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
| Metabolism | Barium sulfate is not metabolized. It is eliminated unchanged in the feces. No hepatic or renal metabolism occurs due to lack of systemic absorption. |
| Excretion | Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate. |
| Half-life | Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage. |
| Protein binding | Not applicable; no systemic absorption, thus no protein binding. |
| Volume of Distribution | Not applicable; no systemic absorption, thus Vd is undefined. |
| Bioavailability | Oral: 0% (barium sulfate is not absorbed; it remains within the GI lumen). |
| Onset of Action | Oral administration: immediate coating of esophageal and gastric mucosa upon ingestion; visualization begins within seconds. |
| Duration of Action | Oral: effects last until the contrast agent passes through the GI tract (approximately 30–60 minutes for upper GI series; 6–24 hours for complete transit). |
| Molecular Weight | 233.39 |
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
| Dosage form | PASTE |
| Renal impairment | No dose adjustment needed; not systemically absorbed. |
| Liver impairment | No dose adjustment needed; not systemically absorbed. |
| Pediatric use | Neonates: 5-10 mL/kg orally once; Infants/Children: 30-60 mL orally once for upper GI, 60-90 mL for small bowel. Maximum total dose 240 mL. |
| Geriatric use | No specific dose adjustment; use lowest effective volume due to aspiration risk and constipation propensity. |
| 1st trimester | VARIBAR PUDDING contains barium sulfate, which is not absorbed systemically. No known teratogenic risk from local GI use. However, radiation exposure from fluoroscopy during administration should be minimized in pregnancy. |
| 2nd trimester | Same as T1. Barium sulfate remains unabsorbed; minimal risk to fetus. Consider benefit-risk of radiation exposure. |
| 3rd trimester | Same as T1. Barium sulfate is not absorbed. No known fetal harm. Radiation risk should be considered. |
Clinical note
Comprehensive clinical and safety monograph for VARIBAR PUDDING (VARIBAR PUDDING).
| Placental transfer | Barium sulfate is not absorbed from the gastrointestinal tract; therefore, placental transfer is negligible. No significant systemic levels expected. |
| Breastfeeding | Barium sulfate is not systemically absorbed, and any passage into breast milk is negligible. It is considered compatible with breastfeeding. The procedure-related radiation exposure is minimal and not a contraindication. |
■ FDA Black Box Warning
None
| Serious Effects |
Known or suspected gastrointestinal perforationKnown obstruction of the gastrointestinal tractKnown hypersensitivity to barium sulfate or any excipientSevere aspiration riskPyloric stenosis (relative, but often considered absolute)
| Precautions | Risk of aspiration: can cause chemical pneumonitis if aspirated into lungs; use with caution in patients with swallowing difficulties or impaired gag reflex., Risk of bowel obstruction or perforation: contraindicated in patients with known or suspected bowel obstruction, perforation, or fistula unless specifically indicated., Hypersensitivity reactions: rare but possible; have resuscitation equipment available., Constipation: can cause impaction, especially in patients with slow transit or dehydration; ensure adequate hydration post-procedure., Suspected GI perforation: avoid use as extravasation can cause peritonitis and granuloma formation. |
| Food/Dietary | No food or drink should be taken for at least 1 hour before the exam unless directed otherwise. Avoid dairy products prior to the exam as they may interfere with coating. After the exam, increase fluid intake to prevent constipation. |
Loading safety data…
| Lactation Rating | L1 (Compatible) |
| Teratogenic Risk | Not absorbed systemically; no teratogenic risk in any trimester. |
| Fetal Monitoring | None required due to lack of systemic absorption. |
| Fertility Effects | No known effect on fertility. |
| Clinical Pearls | VARIBAR PUDDING (barium sulfate) is used for opacification of the gastrointestinal tract during fluoroscopic exams. Administer orally; ensure patient is well-hydrated. Monitor for aspiration risk, especially in elderly or dysphagic patients. Use with caution in suspected bowel obstruction or perforation; contraindicated if GI tract perforation is suspected. |
| Patient Advice | Take exactly as directed; do not skip doses unless instructed. · Inform your doctor if you have a history of bowel obstruction, perforation, or allergies to barium. · Drink plenty of water after the exam to help eliminate barium. · Stool may appear white or light-colored for 1–2 days; this is normal. · Seek immediate medical attention if you experience severe abdominal pain, vomiting, or inability to pass stool. |